[Vancomycin-induced linear IgA bullous dermatosis].
Lesueur
Arnaud
A
Lefort
Catherine
C
Gauthier
Jean Michel
JM
Andrivet
Pierre
P
D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001706:Biopsy; D003176:Complement C3 / Q000378:metabolism; D003875:Drug Eruptions / Q000175:diagnosis* / Q000276:immunology / Q000473:pathology; D016109:Epidermolysis Bullosa, Junctional / Q000139:chemically induced* / Q000276:immunology / Q000473:pathology; D006801:Humans; D007070:Immunoglobulin A / Q000378:metabolism*; D008297:Male; D016106:Methicillin Resistance; D011023:Pneumonia, Staphylococcal / Q000188:drug therapy*; D012867:Skin / Q000276:immunology / Q000473:pathology; D014640:Vancomycin / Q000009:adverse effects* / Q000627:therapeutic use
D000900:Anti-Bacterial Agents; D003176:Complement C3; D007070:Immunoglobulin A; D014640:Vancomycin